Thiazolidinediones and lowered HDL cholesterol

Diabetes Care

Volumn 28, Issue 9, 2005, Pages 2329-2330

  Savage, Ruth L ^a   Kiuru, Anne ^b  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b UPPSALA MONITORING CENTRE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ROSIGLITAZONE;

ADULT; ARTICLE; CASE REPORT; CHOLESTEROL BLOOD LEVEL; DATA BASE; DIABETES MELLITUS; DRUG MECHANISM; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; HUMAN; HYPERCHOLESTEROLEMIA; MALE; TREATMENT OUTCOME; VIGIBASE;

EID: 24144440448     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.28.9.2329-a     Document Type: Article

References (4)

1. Sarker A, Semple RK, Dineen SF, O'Rahilly S, Martin SC: Severe hypo-α-lipoproteinemia during treatment with rosiglitazone. Diabetes Care 27:2577-2580, 2004
2. Normen L, Frohlich J, Montaner J, Harris M, Elliott T, Bondy G: Combination therapy with fenofibrate and rosiglitazone paradoxically lowers serum HDL cholesterol. Diabetes Care 27:2241-2242, 2004
3. Ebcioglu Z, Morgan J, Carey C, Capuzzi D: Paradoxical lowering of high-density lipoprotein cholesterol level in 2 patients receiving fenofibrate and a thiazolidinedione (Letter). Ann Intern Med 139:W80, 2003
4. Bate A, Lindquist M, Edwards IR, Olsson S, Orre R, Lansner A, DeFreitas RM: A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol 54315-54321, 1998